other products

mycology research product

research & development

mycology research product

Quality Standards

Mycology Research Laboratories Ltd. (MRL) markets mushroom nutrition products that are cultivated in accordance with both the California Organic Food Act of 1990 and the EU organic regulation (EEC 2092/91). All MRL products are manufactured to food grade GMP standards in Holland.

Keyword oncogynecological disease

December'13

In this issue, Prof. Amin Karmali compares in vitro the impact of proteolytic enzymes on the beta-glucan content, enzyme content and secondary metabolite content between a biomass form of Ganoderma lucidum (Reishi) versus an extracted form of Ganoderma lucidum. Various forms of Beta 1,3 -1,6 glucan activities are measured, such as water soluble fraction, hot water fraction, NaOH fraction, KOH fraction and HCI fraction. In terms of enzymes, measurements, super-oxide dismutase activity (SOD), peroxidase activity, Glucoamylase/Beta-glucanasase activity, Glucose 2-oxdase activity, Cytochrome “P-450”, Cytochrome P 450 reductase were taken in the absence of proteolytic enzymes and in the presence of proteolytic enzymes.

A copy of Professor Todor Chernev´s poster presentation entitled “Coriolus-MRL supplementation in patients infected with low-risk and high-risk HPV subtypes - Bulgarian experience. The original poster presentation on the use of Coriolus-MRL in two separate studies (100 patients and 200 patients respectively) reinforces the original clinical work by Dr. Silva Couto in which Coriolus-MRL is a useful tool for gynecologists when working with HPV LSIL patients with High risk viral subtypes.

Presented is an English translation of a 2008 Bulgarian Medline article on Coriolus-MRL by Dr. Yuliyana Bogdanova (PhD) from the Bulgarian Institute of Botany, Bulgarian Academy of Sciences, in Sofia, Bulgaria. The study outlines the clinical development of Coriolus-MRL.

Finally, Professor Vittorio Calabrese (University of Catania, Italy) and Professor Tito Fernandes (Scientific Director, University of Lurio, Mozambique) propose to use mushroom nutrition in Alzheimer´s patients. This two-part proposal is focused on the premise that the HSV1 virus could trigger the biochemical events that lead to the development of Alzheimer´s disease. The paper relies on work conducted by researchers working with Dr. Frank M. LaFerla at the at the department of Neurobiology and Behavior at the university of California Irvine, in Irvine California and to work conducted by researchers working with Professor Ruth Itzhaki in the University of Manchester in the United Kingdom. As a first step, the proposed protocol seeks to verify that Coriolus-MRL when combined equally with Hericium-MRL can activate Lipoxin A4 (LXA4) activity which has been postulated as a novel approach to addressing the symptoms associated with Alzheimer´s disease. With confirmation that mushroom nutrition can activate LXA4 activity, then a small scale human study will be initiated.